November 17 2009 - Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE® smallpox vaccine with a total prospective value of USD 40 million.
The details can be read here.
No comments:
Post a Comment